Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Lance Armstrong Fraud Inquiry Considered, Times Says

May 26 (Bloomberg) -- U.S. authorities are in the early stages of considering whether to investigate Lance Armstrong and other cyclists for fraud and conspiracy tied to doping, the New York Times reported.

The inquiry is into whether Armstrong, his teammates and the owners of his former cycling teams conspired to defraud sponsors by using performance-enhancing drugs to gain more money and prizes, the newspaper said, citing an unnamed person familiar with the investigation. Authorities also want to know whether money from the U.S. Postal Service, which sponsored Armstrong’s team from 1996 to 2004, was used to buy performance-enhancing drugs.

Armstrong could face particular scrutiny because he had an ownership stake in Tailwind Sports, the company that owned several of his past cycling teams, the Times said. Jeff Novitzky, a federal agent now with the Food and Drug Administration who has led several doping investigations, is playing a direct role in this inquiry, the newspaper said.

Should the investigation proceed, Armstrong looks forward to being “totally vindicated,” his Team RadioShack said in a statement posted on his website.

“We understand that responsible anti-doping organizations and governmental agencies have an obligation to investigate allegations of wrongdoing, even when those allegations are baseless, incredible and made by people with improper motives,” the statement said. “At the same time, much of what has been reported in the press is false, sensational and unprofessional.”

A telephone message left for FDA spokeswoman Meghan Scott wasn’t immediately returned, nor was a message left for U.S. Drug Enforcement Administration spokesman Rusty Payne.

To contact the reporter on this story: Mason Levinson in New York at mlevinson@bloomberg.net.

To contact the editor responsible for this story: Michael Sillup at msillup@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.